Evidence map›Paper›PMID 30368729›Full record

ArticlePathology oncology research : POR2019

Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.

Marcela Chmelarova, Ivana Baranova, Ema Ruszova, Jan Laco, Katerina Hrochova, Eva Dvorakova, Vladimir Palicka

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marcela ChmelarovaInstitute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
Ivana BaranovaInstitute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic. ivana.baranova@fnhk.cz.ORCID http://orcid.org/0000-0001-8273-2595
Ema RuszovaDepartment of Clinical Genetics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Jan LacoThe Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
Katerina HrochovaInstitute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
Eva DvorakovaDepartment of Obstetrics and Gynecology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
Vladimir PalickaInstitute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
Charles University · CZUniversity Hospital Hradec Králové · CZ

Funding

Ministerstvo Školství, Mládeže a Tělovýchovy BBMRI, LM2015089Ministerstvo Zdravotnictví Ceské Republiky UHHK, 00179906
6 · The paper itself

Abstract

Epigenetic aberrations are well known to play an important role in carcinogenesis, and also have a great potential to serve as biomarkers in many types of cancers, including ovarian cancer in which sensitive and specific biomarkers and detection methods are critically needed. The aim of this study was to investigate methylation of cadherin genes CDH10, CDH13 and CDH18 in ovarian cancer tissue by comparison with control tissue. The study group consisted of 38 patients with ovarian cancer and 25 control patients. For detection of epigenetic events we used next generation sequencing, the most important data were confirmed using high-resolution melting analysis and real-time PCR. We observed significantly higher methylation in CDH13, sporadic methylation in CDH10 and loss of methylation in CDH18 in the ovarian cancer group compared with the control group. These observations suggest that changes in methylation of cadherin genes may be one of the major mechanisms associated with ovarian cancer progression. In addition, because of the high frequency of methylation of the CDH13 gene in the early stages of ovarian cancer, the analyzed CpG sites might be good targets for next study of potential ovarian cancer screening biomarkers.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticAdenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorCadherinsCase-Control StudiesCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedOvarian NeoplasmsBiomarkers, TumorCadherinsH-cadherinCadherinsEpigeneticsMethylationNext generation sequencingOvarian cancer

Identifiers

PMID30368729
OpenAlexW2898396847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.